178 related articles for article (PubMed ID: 38483383)
1. Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.
Trapani D; Katrini J; Curigliano G
JAMA Oncol; 2024 May; 10(5):563-564. PubMed ID: 38483383
[TBL] [Abstract][Full Text] [Related]
2. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.
Richardson DL; Seward SM; Moore KN
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1057-1071. PubMed ID: 30390760
[TBL] [Abstract][Full Text] [Related]
3. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
[TBL] [Abstract][Full Text] [Related]
4. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
5. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
Fazekas-Singer J; Singer J; Jensen-Jarolim E
Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
[TBL] [Abstract][Full Text] [Related]
7. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Lee HC; Raje NS; Landgren O; Upreti VV; Wang J; Avilion AA; Hu X; Rasmussen E; Ngarmchamnanrith G; Fujii H; Spencer A
Leukemia; 2021 Jan; 35(1):255-258. PubMed ID: 32317775
[No Abstract] [Full Text] [Related]
10. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
11. [Antibody-drug conjugates in oncology. Recent success of an ancient concept].
Beck A; Dumontet C; Joubert N
Med Sci (Paris); 2019 Dec; 35(12):1034-1042. PubMed ID: 31903915
[TBL] [Abstract][Full Text] [Related]
12. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
13. [Antibody-drug conjugates in oncology. New strategies in development].
Beck A; Dumontet C; Joubert N
Med Sci (Paris); 2019 Dec; 35(12):1043-1053. PubMed ID: 31903916
[TBL] [Abstract][Full Text] [Related]
14. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
15. [Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer].
Zhu Y; Wang Z
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):468-476. PubMed ID: 35899443
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for CD30-positive tumours.
Masuda S; Miyagawa S; Nakamura T; Khurram MA; Sawa Y
Lancet Oncol; 2016 Sep; 17(9):e371. PubMed ID: 27599139
[No Abstract] [Full Text] [Related]
17. Antibody-drug conjugates in breast cancer.
Bardia A
Clin Adv Hematol Oncol; 2017 Apr; 15(4):251-254. PubMed ID: 28591100
[No Abstract] [Full Text] [Related]
18. Evolving Paradigms of Personalized Medicine in Oncology.
Dhingra K
Natl Med J India; 2017; 30(6):305-308. PubMed ID: 30117439
[No Abstract] [Full Text] [Related]
19. Sacituzumab govitecan activity in advanced breast cancer.
Burki TK
Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
[No Abstract] [Full Text] [Related]
20. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]